bevacizumab + nivolumab + paclitaxel

This is a combination regimen consisting of three drugs: - **Bevacizumab** is a monoclonal antibody that inhibits vascular endothelial growth factor A (VEGF-A), thereby blocking angiogenesis (the formation of new blood vessels) in tumors. - **Nivolumab** is a monoclonal antibody immune checkpoint inhibitor targeting programmed cell death protein 1 (PD-1), enhancing T-cell mediated anti-tumor immunity. - **Paclitaxel** is a small molecule chemotherapeutic agent that stabilizes microtubules, inhibiting cell division and inducing apoptosis in cancer cells. The combination has been studied as first-line therapy for advanced non-squamous non-small cell lung cancer (NSCLC) without EGFR, ALK, or ROS1 alterations. Clinical trials have shown improved progression-free survival and overall survival compared to standard regimens. The mechanism combines antiangiogenic effects, immune checkpoint blockade, and cytotoxic chemotherapy for synergistic antitumor activity[1][2][3].